We further evaluated the gene expression of RORA and its target genes in PBMC, and the results showed that maternal diabetes (STZ/VEH) treatment significantly decreased mRNA levels of RORA and its target genes CYP19A1 and SOD2 (P < 0.0001) compared to CTL/VEH treatment, and STZ/MnTBAP treatment completely, while STZ/SR1078 treatment partly, reversed this effect (see Fig. 3f). The gene discussed is CYP19A1; the disease is diabetes mellitus.